Alkermes, Inc. (NASDAQ:ALKS)

CAPS Rating: 3 out of 5

A biotechnology company that develops innovative medicines designed to yield better therapeutic outcomes and improve the lives of patients with serious disease.

Recs

1
Player Avatar lovinoptions (79.72) Submitted: 7/24/2009 1:34:48 PM : Outperform Start Price: $11.59 ALKS Score: +189.09

Very high profit margin

Very low P/E

Very high forward P/E

Earnings expected to grow at a rate of 42% over the next 5 years.

Very little debt (LT Debt/Equity is .12)

I put this stock at $30-40 by sometime next year. (Brave I know)

Enjoy!
DH

Featured Broker Partners


Advertisement